Novel agents and strategies for overcoming EGFR TKIs resistance

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Epidermal growth factor receptor (EGFR) is a key therapeutic target in lung cancer.
• EGFR tyrosine kinase inhibitors (TKIs) significantly improve progression-free survival (PFS) in patients with EGFR mutations.
• Acquired resistance (AR) to EGFR TKIs is an inevitable challenge in lung cancer treatment.

Purpose of the Study:

• To review novel agents for overcoming acquired resistance (AR) to EGFR TKIs.
• To discuss emerging therapeutic strategies for patients with EGFR-mutated lung cancer who develop resistance.
• To provide an overview of current clinical practices for managing AR to EGFR TKIs.

Main Methods:

• Literature review of novel agents targeting signaling pathways.
• Analysis of therapeutic strategies for overcoming acquired resistance (AR).
• Synthesis of information on clinical practices for managing AR to EGFR TKIs.

Main Results:

• EGFR TKIs offer significant PFS benefits but acquired resistance (AR) eventually occurs.
• Various small molecule agents and monoclonal antibodies (McAb) show promise in overcoming AR.
• Multiple therapeutic strategies are being investigated and used in clinical practice.

Conclusions:

• Overcoming acquired resistance (AR) to EGFR TKIs is crucial for improving long-term outcomes in lung cancer.
• Novel agents and therapeutic strategies are essential for managing resistance.
• Continued research into overcoming AR is vital for advancing lung cancer treatment.